Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity

Fig. 7

CP/CPPS pain symptoms were relieved after treatment. A Expression of CCL2 mRNA in EAP mice and control group mice. B Ca2+ influx in DRGs following treatment with different concentrations of CCL2. Low: 100 ng/mL; high: 300 ng/mL (n = 3 per group). CAP, capsaicin (300 nM). C At 30 days, the pelvic pain response of mice in the saline, MSC, and IL-1β-primed MSC groups; at 45 days, the pelvic pain response of mice in the saline, MSC, and IL-1β-primed MSC groups; at 30 and 45 days, the paw pain of mice in the saline, MSC, and IL-1β-primed MSC groups (n = 6 per group). D Expression of CCL2 in the prostates of the saline, MSC, and IL-1β-primed MSC groups by IF (n = 6 per group, bar = 50 μm). E Expression of CCL2 in the prostates of the saline, MSC, and IL-1β-primed MSC groups by Western blotting (n = 6 per group). F Expression of CGRP in the saline, MSC, and IL-1β-primed MSC groups by IF (n = 6 per group, bar = 50 μm). G Expression of CCL2 and TRPV1 in the DRGs of the saline, MSC, and IL-1β-primed MSC groups by IF (n = 6 per group, bar = 50 μm). Error bars indicate SD. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page